Shanmuganathan Chandrakasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shanmuganathan Chandrakasan has a total of 394 co-authors. Here are the top co-authors by number of shared publications:
Chengyu Prince
11 shared publicationsDeepak Kumar
10 shared publicationsMichael Briones
10 shared publicationsLaura Lucas
Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
7 shared publications- Sampath Prahalad
Departments of Pediatrics and Human Genetics Emory University School of Medicine and Children's Healthcare of Atlanta Atlanta Georgia
6 shared publications Sunita Park
Department of Pathology, Children’s Healthcare of Atlanta, Atlanta, GA
6 shared publications
Latest Publications
- 6 August 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (4) , 1152-1156
B-cell dysregulation and broad autoantibody repertoire underlie the immunopathology of MIS-C
- 6 August 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (4) , 1152-1156
B-cell dysregulation and broad autoantibody repertoire underlie the immunopathology of MIS-C
- Open Access
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Open AccessNewborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- 27 April 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (5) , e175-e182
Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia Therapy
Although some children with B-cell acute lymphoblastic leukemia (B-ALL) receive intravenous immunoglobulin (IVIG) during conventional therapy, supplementation practices vary, and data describing the indications and their impact are lacking. In this single-institution cohort of children with B-ALL receiving conventional chemotherapy, we evaluate associations of patient and disease characteristics with IVIG supplementation, describe infection-related outcomes by IVIG receipt, and describe outcomes after IVIG supplementation. Multivariable logistic regression models identified factors associated with IVIG receipt. Of 373 eligible patients with B-ALL who did not receive immune therapy, 251 (67.3%) had an IgG level checked, and 114 (30.6%) received IVIG. The median IgG nadir was lower in IVIG recipients versus nonrecipients (404 vs. 675 mg/dL, P P P 2 severe infections during treatment (OR=2.57, 95% CI=1.28-5.18), and higher for National Cancer Institute standard risk patients with IgG nadir <500 mg/dL (OR=7.45, 95% CI=3.54-15.70). For IVIG recipients, the rate of emergency department visits, severe infections, and febrile neutropenia episodes was 5.4, 1.9, and 1.1 per 1000 treatment days, respectively, during IVIG supplementation. Among children with B-ALL receiving conventional chemotherapy, clinical characteristics differ between IVIG recipients and nonrecipients. Uniform IgG measurements during therapy may guide supplementation decisions, especially in the era of frontline immunotherapy.
- 27 April 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (5) , e175-e182
Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia Therapy
Although some children with B-cell acute lymphoblastic leukemia (B-ALL) receive intravenous immunoglobulin (IVIG) during conventional therapy, supplementation practices vary, and data describing the indications and their impact are lacking. In this single-institution cohort of children with B-ALL receiving conventional chemotherapy, we evaluate associations of patient and disease characteristics with IVIG supplementation, describe infection-related outcomes by IVIG receipt, and describe outcomes after IVIG supplementation. Multivariable logistic regression models identified factors associated with IVIG receipt. Of 373 eligible patients with B-ALL who did not receive immune therapy, 251 (67.3%) had an IgG level checked, and 114 (30.6%) received IVIG. The median IgG nadir was lower in IVIG recipients versus nonrecipients (404 vs. 675 mg/dL, P P P 2 severe infections during treatment (OR=2.57, 95% CI=1.28-5.18), and higher for National Cancer Institute standard risk patients with IgG nadir <500 mg/dL (OR=7.45, 95% CI=3.54-15.70). For IVIG recipients, the rate of emergency department visits, severe infections, and febrile neutropenia episodes was 5.4, 1.9, and 1.1 per 1000 treatment days, respectively, during IVIG supplementation. Among children with B-ALL receiving conventional chemotherapy, clinical characteristics differ between IVIG recipients and nonrecipients. Uniform IgG measurements during therapy may guide supplementation decisions, especially in the era of frontline immunotherapy.
- Open Access
- 1 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1653344
Next generation targeted non-genotoxic conditioning for hematopoietic stem cell and hematopoietic stem cell-based gene therapy
Hematopoietic stem cell transplant (HSCT) and hematopoietic stem cell (HSC)-based gene therapy, including gene editing approaches, offer a promising strategy for addressing numerous lymphohematopoietic genetic defects. Although significant progress has been made since the first HSCT over 60 years ago, the widespread application of allogeneic HSCT and autologous gene therapy is still hindered by the need for pre-transplant conditioning. The eradication of host HSCs and their progeny is widely thought to be necessary to create “space” in the bone marrow niche and enable long term engraftment of transplanted cells. However, despite decades of research, alkylating agents such as busulfan, melphalan and treosulfan or total body irradiation still remain the backbone of most HSCT condidtioning regimens. These genotoxic conditioning agents are non-targeted and leave patients susceptible to infections, infertility, organ toxicities, and secondary malignancies. As a result, there is an urgent need to develop alternative, non-genotoxic conditioning regimens that can selectively deplete HSCs while sparing cells outside the lymphohematopoietic compartment. A growing body of preclinical and clinical breakthroughs demonstrate the effectiveness of monoclonal antibodies, antibody-drug conjugates, immunotoxins, radioimmunotherapy compounds, and even T cell redirection strategies for achieving targeted HSC elimination. The use of these new agents can transform HSCT, and in this review we aim to highlight the potential and limitations of next-generation, non-genotoxic or minimally toxic conditioning methods. These alternatives to conventional chemoradiation could reduce toxicity and improve the safety of HSC-based gene therapies, ultimately expanding patient access and eligibility for these transformative treatments.
- 1 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1653344
Open AccessNext generation targeted non-genotoxic conditioning for hematopoietic stem cell and hematopoietic stem cell-based gene therapy
Hematopoietic stem cell transplant (HSCT) and hematopoietic stem cell (HSC)-based gene therapy, including gene editing approaches, offer a promising strategy for addressing numerous lymphohematopoietic genetic defects. Although significant progress has been made since the first HSCT over 60 years ago, the widespread application of allogeneic HSCT and autologous gene therapy is still hindered by the need for pre-transplant conditioning. The eradication of host HSCs and their progeny is widely thought to be necessary to create “space” in the bone marrow niche and enable long term engraftment of transplanted cells. However, despite decades of research, alkylating agents such as busulfan, melphalan and treosulfan or total body irradiation still remain the backbone of most HSCT condidtioning regimens. These genotoxic conditioning agents are non-targeted and leave patients susceptible to infections, infertility, organ toxicities, and secondary malignancies. As a result, there is an urgent need to develop alternative, non-genotoxic conditioning regimens that can selectively deplete HSCs while sparing cells outside the lymphohematopoietic compartment. A growing body of preclinical and clinical breakthroughs demonstrate the effectiveness of monoclonal antibodies, antibody-drug conjugates, immunotoxins, radioimmunotherapy compounds, and even T cell redirection strategies for achieving targeted HSC elimination. The use of these new agents can transform HSCT, and in this review we aim to highlight the potential and limitations of next-generation, non-genotoxic or minimally toxic conditioning methods. These alternatives to conventional chemoradiation could reduce toxicity and improve the safety of HSC-based gene therapies, ultimately expanding patient access and eligibility for these transformative treatments.
- Top Cited PapersOpen Access
- 30 July 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging
Germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) are associated with infections, including chronic mucocutaneous candidiasis and autoimmunity. Morbidity is high, and disease manifestations can be life-threatening. Curative allogeneic hematopoietic stem cell transplantation (HSCT) historically has had poor outcomes. We identified 36 patients with STAT1 GOF disease, receiving 40 HSCT procedures in 2010–2023, in a combined effort of the EBMT-IEWP and the PIDTC. Median age at first transplant was 11 years (range 1–33). Indications for HSCT were combined immunodeficiency, severe and/or refractory infections, and autoimmunity. Acute GvHD occurred in 22/40 HSCT procedures; 5 patients suffered from grade III/IV acute GvHD. One patient had chronic GvHD. Overall survival was 72.2%, and event-free survival was 55.6%, markedly improved from an earlier report on HSCT for STAT1 GOF disease. Patients with an HCT-CI score of 1 or higher had worse outcome. Pre-treatment with Janus kinase (JAK) inhibitors was associated with better event-free survival.
- 30 July 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (3)
Top Cited PapersOpen AccessImproved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging
Germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) are associated with infections, including chronic mucocutaneous candidiasis and autoimmunity. Morbidity is high, and disease manifestations can be life-threatening. Curative allogeneic hematopoietic stem cell transplantation (HSCT) historically has had poor outcomes. We identified 36 patients with STAT1 GOF disease, receiving 40 HSCT procedures in 2010–2023, in a combined effort of the EBMT-IEWP and the PIDTC. Median age at first transplant was 11 years (range 1–33). Indications for HSCT were combined immunodeficiency, severe and/or refractory infections, and autoimmunity. Acute GvHD occurred in 22/40 HSCT procedures; 5 patients suffered from grade III/IV acute GvHD. One patient had chronic GvHD. Overall survival was 72.2%, and event-free survival was 55.6%, markedly improved from an earlier report on HSCT for STAT1 GOF disease. Patients with an HCT-CI score of 1 or higher had worse outcome. Pre-treatment with Janus kinase (JAK) inhibitors was associated with better event-free survival.
- Open Access
- 27 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (10) , 2436-2437
Breaking the cycle: PRMTs and secondary HLH relief
- 27 May 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (10) , 2436-2437
Open AccessBreaking the cycle: PRMTs and secondary HLH relief
- 9 May 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (6) , 1748-1749
Maternal Microchimerism, a Red Flag or a Red Herring in Very-Early-Onset Inflammatory Bowel Disease?
- 9 May 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (6) , 1748-1749
Maternal Microchimerism, a Red Flag or a Red Herring in Very-Early-Onset Inflammatory Bowel Disease?
- Open Access
- 14 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1952-1965
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8–negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm–driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have “oligocentric” lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.
- 14 April 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (8) , 1952-1965
Open AccessCharacterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8–negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm–driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have “oligocentric” lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.
- Open Access
- 4 April 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (6) , 1317-1324
Expert-Based, Institutional Approaches for Reducing the Diagnostic Odyssey of Patients With Inborn Errors of Immunity
- 4 April 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (6) , 1317-1324
Open AccessExpert-Based, Institutional Approaches for Reducing the Diagnostic Odyssey of Patients With Inborn Errors of Immunity
- 11 March 2025
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 45 (2) , 173-188
Biomarkers of Immune Dysregulation and What They Tell Us
- 11 March 2025
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 45 (2) , 173-188
Biomarkers of Immune Dysregulation and What They Tell Us